Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of NASDAQ EVGN opened at $1.55 on Wednesday. The business has a fifty day moving average price of $1.59 and a two-hundred day moving average price of $2.67. The stock has a market capitalization of $8.32 million, a PE ratio of -0.35 and a beta of 1.30. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $10.40.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) EPS for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.